JP2024500242A5 - - Google Patents
Info
- Publication number
- JP2024500242A5 JP2024500242A5 JP2023538891A JP2023538891A JP2024500242A5 JP 2024500242 A5 JP2024500242 A5 JP 2024500242A5 JP 2023538891 A JP2023538891 A JP 2023538891A JP 2023538891 A JP2023538891 A JP 2023538891A JP 2024500242 A5 JP2024500242 A5 JP 2024500242A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- seq
- sequence number
- antibody
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20216800 | 2020-12-23 | ||
| EP20216800.1 | 2020-12-23 | ||
| PCT/EP2021/087495 WO2022136642A1 (en) | 2020-12-23 | 2021-12-23 | Tumor-specific claudin 18.2 antibody-drug conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500242A JP2024500242A (ja) | 2024-01-05 |
| JP2024500242A5 true JP2024500242A5 (cg-RX-API-DMAC7.html) | 2025-01-17 |
Family
ID=73856974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023538891A Pending JP2024500242A (ja) | 2020-12-23 | 2021-12-23 | 腫瘍特異的クローディン１８．２抗体と薬物との複合体 |
Country Status (14)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230030674A1 (en) * | 2019-12-06 | 2023-02-02 | Sotio Biotech A.S. | Humanized cldn18.2 antibodies |
| KR20240043797A (ko) | 2021-08-13 | 2024-04-03 | 싸이튠 파마 | 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합 |
| JP2025529210A (ja) | 2022-09-01 | 2025-09-04 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法 |
| CN115368435B (zh) * | 2022-09-06 | 2025-04-18 | 联宁（苏州）生物制药有限公司 | 一种抗体偶联药物连接子set0568的合成方法 |
| WO2024137619A1 (en) | 2022-12-20 | 2024-06-27 | Bolt Biotherapeutics, Inc. | Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof |
| WO2024173384A1 (en) | 2023-02-14 | 2024-08-22 | Bolt Biotherapeutics, Inc. | Aza-benzazepine immunoconjugates, and uses thereof |
| CN119139489A (zh) * | 2023-06-16 | 2024-12-17 | 信达生物制药(苏州)有限公司 | 靶向Claudin18.2的抗体-药物偶联物用于治疗实体瘤的方法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050214A1 (en) | 2024-08-27 | 2026-03-05 | Bolt Biotherapeutics, Inc. | Anti-claudin, tlr agonist immunoconjugates and uses thereof |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2343001A1 (en) | 1998-09-16 | 2000-03-23 | Zymogenetics, Inc. | Stomach polypeptide zsig28 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| AU2009270988A1 (en) * | 2008-07-15 | 2010-01-21 | Genentech, Inc. | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| CN104428007B (zh) * | 2012-07-09 | 2018-03-16 | 基因泰克公司 | 包含抗cd22抗体的免疫缀合物 |
| JP6499079B2 (ja) | 2012-11-13 | 2019-04-10 | バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ | クローディンを発現するガン疾患を処置するための剤 |
| WO2014127785A1 (en) | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| WO2016102679A1 (en) | 2014-12-23 | 2016-06-30 | Nbe-Therapeutics Ag | Binding protein drug conjugates comprising anthracycline derivatives |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| ES2979068T3 (es) | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
| EP3634401A1 (en) * | 2017-06-07 | 2020-04-15 | Silverback Therapeutics, Inc. | Antibody construct conjugates |
| SG11202007055QA (en) * | 2018-03-08 | 2020-09-29 | Phanes Therapeutics Inc | Anti-claudin 18.2 antibodies and uses thereof |
| WO2019175617A1 (en) | 2018-03-10 | 2019-09-19 | Pratik Sharma | Data redundancy and elimination module |
| EP3765522A4 (en) * | 2018-03-14 | 2022-05-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODIES |
| US11059887B2 (en) * | 2018-05-18 | 2021-07-13 | Lanova Medicines Limited Company | Anti-claudin 18.2 antibodies and uses thereof |
| WO2019242505A1 (zh) | 2018-06-17 | 2019-12-26 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| JP7513605B2 (ja) | 2018-07-18 | 2024-07-09 | アスクジーン・ファーマ・インコーポレイテッド | 新規な抗体ならびにそれを調製および使用するための方法 |
| US12054543B2 (en) | 2018-07-25 | 2024-08-06 | Accurus Biosciences, Inc. | CLDN 18.2-specific monoclonal antibodies and methods of use thereof |
| WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
| WO2020038404A1 (zh) | 2018-08-22 | 2020-02-27 | 瑞阳(苏州)生物科技有限公司 | 抗人claudin 18.2单克隆抗体及其应用 |
| KR20210050547A (ko) | 2018-08-27 | 2021-05-07 | 난징 산홈 팔마세우티칼 컴퍼니 리미티드 | 항-클라우딘18.2 항체 및 이의 용도 |
| JP2022511394A (ja) | 2018-09-30 | 2022-01-31 | カファ セラピューティクス リミテッド | Ｃｌｄｎ１８の抗体及び化学療法薬の併用療法 |
| EP3872093A4 (en) | 2018-10-22 | 2022-10-19 | Shanghai Genbase Biotechnology Co., Ltd. | ANTI-CLDN18.2 ANTIBODIES AND USES THEREOF |
| KR20210110339A (ko) | 2018-12-28 | 2021-09-07 | 난징 진스크립트 바이오테크 컴퍼니 리미티드 | 클라우딘18.2 결합 모이어티 및 그 용도 |
| CN119350498A (zh) | 2018-12-28 | 2025-01-24 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| EP3902824A4 (en) | 2018-12-28 | 2023-01-04 | Sparx Therapeutics Inc. | FOR CLAUDIN 18.2 SPECIFIC BINDING MOLECULES, COMPOSITIONS AND METHODS OF TREATMENT OF CANCER AND OTHER DISEASES |
| CN109762067B (zh) | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| SG11202108398YA (en) | 2019-02-01 | 2021-08-30 | Novarock Biotherapeutics Ltd | Anti-claudin 18 antibodies and methods of use thereof |
| KR20210148216A (ko) | 2019-04-01 | 2021-12-07 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | 항-클라우딘 18.2 항체 및 이의 응용 |
| US20230030674A1 (en) * | 2019-12-06 | 2023-02-02 | Sotio Biotech A.S. | Humanized cldn18.2 antibodies |
| WO2021130291A1 (en) * | 2019-12-23 | 2021-07-01 | SOTIO a.s. | Tumor-specific claudin 18.2 antibodies |
| CN111808194B (zh) | 2020-07-13 | 2021-04-20 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
-
2021
- 2021-12-23 TW TW110148442A patent/TW202241519A/zh unknown
- 2021-12-23 PE PE2023001921A patent/PE20231561A1/es unknown
- 2021-12-23 JP JP2023538891A patent/JP2024500242A/ja active Pending
- 2021-12-23 AU AU2021405049A patent/AU2021405049A1/en not_active Abandoned
- 2021-12-23 WO PCT/EP2021/087495 patent/WO2022136642A1/en not_active Ceased
- 2021-12-23 US US18/269,240 patent/US20240100180A1/en active Pending
- 2021-12-23 IL IL302894A patent/IL302894A/en unknown
- 2021-12-23 EP EP21847946.7A patent/EP4267194A1/en not_active Withdrawn
- 2021-12-23 CA CA3199830A patent/CA3199830A1/en active Pending
- 2021-12-23 CN CN202180085938.6A patent/CN116635085A/zh active Pending
- 2021-12-23 MX MX2023007644A patent/MX2023007644A/es unknown
- 2021-12-23 KR KR1020237024767A patent/KR20230124037A/ko not_active Withdrawn
-
2023
- 2023-05-11 ZA ZA2023/05221A patent/ZA202305221B/en unknown
- 2023-06-16 CL CL2023001800A patent/CL2023001800A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500242A5 (cg-RX-API-DMAC7.html) | ||
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| KR20220025861A (ko) | 항체 약물 복합체, 이의 중간체, 제조 방법 및 용도 | |
| JP6328648B2 (ja) | 新規薬物−タンパク質コンジュゲート | |
| JP2026026483A (ja) | 標的化デンドリマー複合体 | |
| CN110575547B (zh) | 靶向于tf的抗体-药物偶联物及其制法和用途 | |
| JP2018140997A (ja) | 抗体−薬剤コンジュゲート | |
| JP2024501894A5 (cg-RX-API-DMAC7.html) | ||
| KR20140139480A (ko) | 항체-약물 접합체 및 관련 화합물, 조성물, 및 방법 | |
| JP2024167209A (ja) | ツブリシン及びタンパク質－ツブリシンコンジュゲート | |
| US20040166115A1 (en) | Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics | |
| US12539336B2 (en) | Antibody, linkers, payload, conjugates and applications thereof | |
| CN110575548A (zh) | 靶向于cd73的抗体-药物偶联物及其制法和用途 | |
| JP2025506768A5 (cg-RX-API-DMAC7.html) | ||
| TW202330618A (zh) | 抗ｃｄｈ６抗體及其抗體－藥物偶聯物 | |
| JP2023509760A (ja) | Ａｌｋ５阻害剤複合体およびその使用 | |
| JP2023542910A5 (cg-RX-API-DMAC7.html) | ||
| WO2024213091A9 (en) | Combination of antibody-drug conjugate and anti-pd-1 antibody, and use thereof | |
| WO2024207177A9 (en) | Antibody, linkers, payload, conjugates and applications thereof | |
| US12419964B2 (en) | Antibody drug conjugate (ADC) targeting Nectin 4 and comprising an exatecan payload | |
| TW202610688A (zh) | 抗ｒｏｒ２抗體－藥物結合物 | |
| US20250332277A1 (en) | Protein tyrosine kinase 7 antibodies and antibody-drug conjugates | |
| TW202602943A (zh) | 抗ｔｒｏｐ２抗體藥物偶聯物及使用方法 | |
| WO2026035986A1 (en) | Humanized anti-cdh17 antibodies and use of the same | |
| NZ747029B2 (en) | Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof |